argenx NV ADR
$ 849.04
2.50%
17 Apr - close price
- Market Cap 53,060,727,000 USD
- Current Price $ 849.04
- High / Low $ 852.28 / 842.93
- Stock P/E 43.30
- Book Value 4.73
- EPS 19.61
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.20 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1035.28
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-30 | 2025-07-15 | 2025-05-07 | 2025-02-27 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 | 2023-05-07 |
| Reported EPS | 6.7945 | 5.18 | 3.2572 | 2.2732 | 0.7125 | 1.39 | 0.45 | -1.04 | -1.68 | -1.25 | -1.69 | -0.71 |
| Estimated EPS | 5.95 | 4.44 | -0.99 | 2.0546 | 1.6979 | 0.03 | -0.98 | -0.86 | -1.7 | -1.54 | -1.73 | -2.26 |
| Surprise | 0.8445 | 0.74 | 4.2472 | 0.2186 | -0.9854 | 1.36 | 1.43 | -0.18 | 0.02 | 0.29 | 0.04 | 1.55 |
| Surprise Percentage | 14.1933% | 16.6667% | 429.0101% | 10.6395% | -58.0364% | 4533.3333% | 145.9184% | -20.9302% | 1.1765% | 18.8312% | 2.3121% | 68.5841% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 5.28 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-04-15 18:40:05
Argenx SE is highlighted as a biotech company with a strong focus on rare autoimmune diseases, leveraging its proprietary Simple Antibody platform for targeted therapies. The company's lead product, Vyvgart, has seen significant regulatory approval and market traction, especially in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. For investors, Argenx offers exposure to high-potential markets with expanding approvals, underpinned by a strategy that balances innovation with strategic partnerships and a focus on underserved medical areas.
2026-04-15 18:39:17
Argenx SE, a biotech company, focuses on developing targeted therapies for rare autoimmune diseases, positioning itself at the forefront of innovation in high-potential markets. Its lead product, Vyvgart, has gained global regulatory approvals, demonstrating the company's scientific execution and market traction. For investors, Argenx represents a strategic bet on specialized medicine within a growing sector, with its robust pipeline and strategic partnerships aiming for sustained profitability and an expanding market presence.
2026-04-14 20:10:17
This article analyzes Argenx SE's potential for growth, focusing on its lead therapy, Vyvgart, in the U.S. and English-speaking rare disease markets. It discusses Argenx's business model centered on high-value immunology products, Vyvgart's competitive advantages in generalized myasthenia gravis (gMG) and emerging indications, and the company's strategic priorities for maximizing market penetration and advancing its pipeline. The report also covers investor relevance, analyst views, and key risks associated with clinical setbacks, competition, and regulatory hurdles.
2026-04-14 20:09:31
This report analyzes Argenx SE, focusing on its lead therapy, Vyvgart, and its expansion into the U.S. rare disease market. It covers the company's business model, competitive landscape, growth catalysts, and risks, providing insights for U.S. and English-speaking market investors. The article highlights Vyvgart's potential for substantial revenue growth through new indications like CIDP and ongoing R&D in other autoimmune diseases.
2026-04-14 12:10:18
Argenx SE is an immunology leader with its proprietary drug Vyvgart, which has shown strong revenue generation, particularly in the U.S. market. The company's business model, based on its "SIMPLE Technology" platform, focuses on developing antibody-based therapies for severe autoimmune diseases and expanding its pipeline beyond Vyvgart. Despite competitive challenges and high R&D costs, Argenx is positioned for significant growth through pipeline expansions and strategic market penetration, especially in the appealing U.S. healthcare landscape.
2026-04-14 03:40:26
Argenx SE is positioned as a leader in immunology due to its proprietary therapy, Vyvgart, which generates strong revenue, particularly in the U.S. market. The company's strategic focus includes expanding Vyvgart's indications and developing a pipeline of other antibody-based therapies for autoimmune diseases. Despite competitive challenges and typical biotech risks, analysts maintain largely positive outlooks, citing the potential for continued growth fueled by U.S. sales and pipeline developments.
